For full experience: Flip your screen for the interactive congress.
[GSKBooth]
VJHemOnc - Herve Avet Loiseau, MD, PhD
Adaptive MRD Global
RESOURCES
Support in the Management of Corneal Adverse Reactions for Your Patients Prescribed BLENREP
Eye Care Evaluation Guide
An Overview of BLENREP and Corneal Adverse Reactions for Eye Care Professionals
Patient wallet card
Understanding the Vision and Eye Changes That May Occur With BLENREP Treatment
Pharmacy eye frop wallet card
Prescribing informations
INDICATION
| BLENREP is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
This indication is approved under accelerated approval. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
BLENREP is not marketed/authorized in all countries. |
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are encouraged to report any suspected adverse reactions to their local GSK office and their national reporting system.INDICATION
